• Ouabain: Selective Na+/K+-ATPase Inhibitor for Applied Resea

  2026-07-28

  Ouabain’s cell-impermeable, highly selective inhibition of Na+/K+-ATPase makes it indispensable for dissecting ion transport and cardiac signaling in both cell and animal models. This guide translates bench research and contemporary literature into actionable protocols, troubleshooting tactics, and workflow enhancements for cardiovascular and cellular physiology studies.

• hiPSC-Derived Intestinal Organoids for Pharmacokinetic Studi

  2026-07-28

  This study introduces a streamlined protocol for generating human induced pluripotent stem cell (hiPSC)-derived intestinal organoids, enabling robust in vitro modeling of drug absorption and metabolism. The organoid system overcomes limitations of traditional models, providing a more physiologically relevant platform for pharmacokinetic research and preclinical evaluation.

• Filipin III: Polyene Macrolide Antibiotic for Cholesterol De

  2026-07-27

  Filipin III delivers superior specificity for cholesterol detection in biological membranes, enabling high-resolution mapping of cholesterol-rich microdomains. This guide details workflow optimization, troubleshooting, and real-world assay tips, with insights from cutting-edge immunometabolic research.

• Filipin III: Polyene Macrolide Antibiotic for Membrane Chole

  2026-07-27

  Filipin III is a polyene macrolide antibiotic that binds specifically to cholesterol in biological membranes, enabling high-sensitivity visualization of cholesterol-rich domains. Its unique fluorescence-quenching mechanism is widely exploited for membrane cholesterol detection. The compound’s selectivity and performance have made it a benchmark tool in cell biology and membrane biochemistry research.

• 25-Hydroxycholesterol Drives Immunosuppressive Macrophage Re

  2026-07-26

  Xiao et al. delineate a molecular pathway in which 25-hydroxycholesterol (25HC) accumulation within tumor-associated macrophages (TAMs) activates lysosomal AMPKα via the GPR155-mTORC1 complex, leading to STAT6 phosphorylation and enhanced immunosuppressive activity. Targeting CH25H, the enzyme generating 25HC, improves anti-tumor responses, with implications for metabolic checkpoint manipulation in cancer immunotherapy.

• PYR-41: Inhibitor of Ubiquitin-Activating Enzyme E1 in Trans

  2026-07-25

  PYR-41, a selective inhibitor of Ubiquitin-Activating Enzyme E1, enables precise dissection of ubiquitin-proteasome system regulation and NF-κB signaling in cancer and immune research. This article delivers actionable protocols, troubleshooting insights, and translational perspectives for advanced users leveraging APExBIO’s trusted PYR-41 reagent.

• Anti-RPS6 Antibody: Optimizing Ribosome Biogenesis Workflows

  2026-07-24

  Unlock advanced cell signaling and ribosome biogenesis research with the Anti-RPS6 (7B10) Mouse Monoclonal Antibody. This article details protocol enhancements, troubleshooting strategies, and real-world workflow optimizations, all grounded in the latest mechanistic insights from pancreatic cancer studies.

• Vitamin C as an Anticancer Agent: Advanced Workflows & Tips

  2026-07-24

  Vitamin C (ascorbic acid) is emerging as a precision tool for cancer research, with dose-dependent effects on tumor cell proliferation and apoptosis. This article distills reference-backed protocols, troubleshooting guidance, and novel mechanistic insights, highlighting APExBIO’s high-purity formulation for reproducibility.

• Ionomycin Free Acid: Precision Tool for Calcium Ionophore Re

  2026-07-23

  Ionomycin free acid unlocks precise manipulation of calcium signaling, powering advanced studies in FAK regulation and oocyte activation. Discover stepwise protocols, troubleshooting strategies, and how the latest TNBC research reshapes practical assay design.

• BV6 (SKU B4653): Enabling Reliable Apoptosis Assays in the L

  2026-07-23

  This scenario-driven article explores how BV6 (SKU B4653), a selective IAP antagonist from APExBIO, addresses persistent challenges in apoptosis, cytotoxicity, and radiosensitization assays. Through real-world laboratory Q&As, we provide evidence-based guidance for optimizing experimental reproducibility and workflow efficiency using BV6.

• Necrostatin-1: RIP1 Kinase Inhibitor for Necroptosis Assays

  2026-07-22

  Necrostatin-1 offers selective, reproducible inhibition of RIP1 kinase, empowering advanced necroptosis assays in tissue injury and inflammation models. Its robust performance in both in vitro and in vivo workflows makes it indispensable for dissecting cell death pathways and accelerating translational research.

• G418 Sulfate (Geneticin): Precision Selection and Antiviral

  2026-07-22

  G418 Sulfate (Geneticin) stands out for its dual role as a gold-standard selection antibiotic and as a potent inhibitor of Dengue virus serotype 2. This guide details experimental workflows, troubleshooting tips, and new directions inspired by recent immunometabolic insights, ensuring researchers can maximize both genetic engineering and antiviral assay success.

• VE-822 ATR Inhibitor: Enhancing Radiosensitization Workflows

  2026-07-21

  VE-822 brings unmatched selectivity and potency to DNA damage response inhibition, enabling researchers to precisely sensitize pancreatic and lung cancer models to chemoradiotherapy. This guide delivers actionable workflows, comparative advantages, and troubleshooting strategies for maximizing VE-822’s impact in both 2D and 3D experimental setups.

• Topotecan as a Topoisomerase I Inhibitor: Clinical Insights

  2026-07-21

  This review synthesizes the pharmacological innovation and clinical data underlying topotecan’s role as a topoisomerase I inhibitor in oncology. Highlighting its mechanism, pharmacokinetics, and comparative efficacy, the article contextualizes topotecan’s position among cytotoxic and alkylating agents, informing researchers on translational and clinical workflow design.

• QPRT Drives Breast Cancer Invasion via Myosin Light Chain Ph

  2026-07-20

  Liu et al. (2021) identify quinolinate phosphoribosyltransferase (QPRT) as a critical promoter of breast cancer invasiveness, acting through enhanced myosin light chain phosphorylation. Their results establish a mechanistic link between NAD+ metabolism and cytoskeletal regulation, highlighting new avenues for targeting metastatic progression.

16316 records 1/1088 page Next 12345 下5页 Last page